EUVIMEDEUVIMED entdecken
Crossref

Plasminogen activator inhibitor-1 genotype 4G/5G associates with skin involvement in Armenian familial Mediterranean fever patients

Gernot Kriegshäuser iD, Hasmik Hayrapetyan iD, Christian Oberkanins iD, Tamara Sarkisian iD

Rheumatology International · 2024

DOI: 10.1007/s00296-024-05653-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology International, 2024. Verfasst von Gernot Kriegshäuser und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Yerevan State Medical University, Koryun 2, Yerevan, 0025, Armenia. gernot.kriegshaeuser@ihrlabor.at. Hauptthemen laut MEDLINE: Plasminogen Activator Inhibitor 1, Familial Mediterranean Fever, Genetic Predisposition to Disease, Genotype. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is little and conflicting data on the role of the plasminogen activator inhibitor-1 (PAI-1, SERPINE1) 4G/5G polymorphism in familial Mediterranean fever (FMF). Therefore this study aimed at evaluating the impact of this polymorphism on the disease course in a cohort of 303 Armenian FMF patients. Genotyping for 12 Mediterranean fever (MEFV) gene mutations and the PAI-1 4G/5G (rs1799762) polymorphism were performed by PCR/reverse-hybridization (StripAssay) and real-time PCR, respectively. PAI-1 genotypes 4G/4G, 4G/5G, and 5G/5G could be identified in 4 (5.88%), 30 (18.63%) and 9 (12.16%) patients with erysipelas-like erythema (ELE), while this was the case for 64 (94.12%), 131 (81.37%), and 65 (87.84%) patients without ELE, respectively (P < 0.033). We have identified a significant relationship between the PAI-1 4G/5G genotype and the occurence of ELE in a relatively large cohort of Armenian FMF patients. Because of conflicting results concerning the impact of this polymorphism on the clinical course of FMF in different populations, further studies are desirable to substantiate the findings reported here.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasminogen Activator Inhibitor 1Familial Mediterranean FeverGenetic Predisposition to DiseaseGenotypeHumansMaleFemaleArmeniaAdultPolymorphism, GeneticMiddle AgedPyrinErysipelasErythemaYoung AdultCytoskeletal ProteinsAdolescentMutation

Stichwörter der Autor:innen

ArmeniaFamilial Mediterranean feverGeneticPlasminogen activator inhibitor 1Polymorphism

Substanzen

Plasminogen Activator Inhibitor 1SERPINE1 protein, humanMEFV protein, humanPyrinCytoskeletal Proteins

Autor:innen und Institutionen

  • Department of Medical Genetics, Yerevan State Medical University, Koryun 2, Yerevan, 0025, Armenia. gernot.kriegshaeuser@ihrlabor.at.
  • Department of Medical Genetics, Yerevan State Medical University, Koryun 2, Yerevan, 0025, Armenia.
  • Center of Medical Genetics and Primary Health Care, Yerevan, Armenia.
  • ViennaLab Diagnostics, Vienna, Austria.

ORCID-Profile: Gernot Kriegshäuser, Hasmik Hayrapetyan, Christian Oberkanins, Tamara Sarkisian

Zitieren

APA

Kriegshäuser, G., Hayrapetyan, H., Oberkanins, C., & Sarkisian, T. (2024). Plasminogen activator inhibitor-1 genotype 4G/5G associates with skin involvement in Armenian familial Mediterranean fever patients. Rheumatology International. https://doi.org/10.1007/s00296-024-05653-x

Vancouver

Kriegshäuser G, Hayrapetyan H, Oberkanins C, Sarkisian T. Plasminogen activator inhibitor-1 genotype 4G/5G associates with skin involvement in Armenian familial Mediterranean fever patients. Rheumatology International. 2024. doi:10.1007/s00296-024-05653-x

BibTeX
@article{Kriegshuser2024,
  author = {Kriegshäuser, Gernot and Hayrapetyan, Hasmik and Oberkanins, Christian and Sarkisian, Tamara},
  title = {Plasminogen activator inhibitor-1 genotype 4G/5G associates with skin involvement in Armenian familial Mediterranean fever patients},
  journal = {Rheumatology International},
  year = {2024},
  doi = {10.1007/s00296-024-05653-x}
}
Kostenlos starten →